Guest: Daniel Bossa
The deluge of advertisements marketing erectile dysfunction medications and testosterone products has empowered many older men to seek medical help for their sexual and genitourinary problems. As a reflection of this historical transition toward increased attention on men’s sexual health, men’s health clinics have sprung up across the United States; concomitantly, testosterone prescription sales increased from about $100 million US dollars in the year 2000 to nearly $2.7 billion in 2013. Today, a majority of testosterone prescriptions are written for men aged 40–64 years (1) even though testosterone is not approved by the US Food and Drug Administration (FDA) for age-related decline in testosterone. Citing the lack of data on long-term benefits and risks of testosterone treatment in older men with age-related decline, the FDA has sounded alarm over the growing off-label use of testosterone. Experts have debated whether prescribing testosterone to older men with testosterone deficiency is disease mongering or whether subsets of older men with testosterone deficiency might benefit from testosterone treatment. Fortunately, several recent randomized controlled trials (RCTs) have provided important information on the efficacy and short-term safety of testosterone treatment in older men. This Viewpoint synthesizes data from epidemiologic studies and RCTs and offers a perspective on a patient-centric approach to treatment decision in older men with testosterone deficiency based on an individualized assessment of benefits and risks.
Play
Sponsorship Inquiries: email This email address is being protected from spambots. You need JavaScript enabled to view it.
Show Notes:
Testosterone replacement in aging men: evidence-based patient-centric study
[9:00] “you aren’t a doctor so you can’t learn”
[13:00] The origins of the AMA.
[16:30] A review of RCT on TRT in mean.
- FDA approval should mean nothing.
[24:00] the “normal” spectrum of testosterone levels.
[31:00] The problems that come with insulin resistance.
[35:10] DHT related hair issues?
[50:00] Lower test levels are associated with higher rates of all cause mortality.
[1:23:20] Resilience from heart damage after a heart attack.
[1:25:40] Diet and the health of testicles.
[1:37:00] The issue with processed foods.
[1:54:00] TRT within 90 days of getting covid?
- The only caution that Carl can think of is if you have higher blood viscosity that isn’t inflammation driven.
[1:58:00] The protective effect of estrogen against parkinson’s and why aromatase inhibitors are not recommended.
- Zinc, vitamin c, inflammation, and liver enzyme levels should all be addressed first.
